Data processing only, treatment is not part of the registry
OtherTreatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment.
NCT Number: NCT07142902
Endoscopic full-thickness resection (EFTR) is a therapeutic option for the treatment of challenging lesions such as subepithelial tumors (SETs) and epithelial neoplasia extending deeper than the mucosa or associated with significant fibrosis. EFTR may offer a less invasive treatment alternative relative to surgical approaches in selected patients.
The gastroduodenal FTRD System (gdFTRD System) is an instrument for endoscopic full-thickness resection or deep partial wall resection and diagnostic tissue acquisition through removal of suitable lesions in the stomach and duodenum.
The prospectively generated data of the gdFTRD registry shall be used to evaluate the application of the gdFTRD in clinical routine, to verify the acceptability of already known risks and to identify unknown risks and complications.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Universitätsklinikum Freiburg - Klinik für Innere Medizin II, Freiburg im Breisgau, Germany
The gdFTRD registry is a registry on cases completed with the gdFTRD System. The gdFTRD System is used for full-thickness resection but the procedure is not part of the study. Only data processing is conducted within the study. For data processing, an EDC system is used.
There are no patient reported outcomes, only physician-entered data on baseline, intervention/procedure, complications/adverse events and follow-up visits.
Automatic plausibility checks have been programmed for quality assurance. Furthermore, warnings and hints will be given on predefined entries not allowed or to double-check values out of normal ranges. No source data verification is planned but data management will check the entries for completeness.
No coding according to MEDRA or similar systems is planned. As the procedure is not part of the study, every participating site must operate according to their own SOPs. The sponsor and CRO have SOPs in place for conducting a study. Furthermore, data protection requirements and all applicable regulations are followed.
The sample size was calculated based results of peer-reviewed publications on the gdFTRD System. As only continuous and categorial variables will be assessed, no separate statistical analysis plan is planned. In case the collected data allows for exploratory post hoc subgroup analysis further tests can be done according to the descriptions in the protocol. Missing data will not be included in the analysis and shall not be imputed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment.
Time frame: Directly post-procedure
Technical success (i.e. target lesion reached and resected; macroscopically complete)
Time frame: Up to 14 days post-procedure
Full-thickness resection (i.e. histologically confirmed full-thickness resection)
Time frame: Up to 14 days post-procedure
R0 resection (i.e. histologically complete lesion resection)
Time frame: Up to 14 days post-procedure
Rate of curative resection (in case of malignant tumors)
Time frame: Intra-procedural and directly post-procedure
Total procedure-related adverse events
Time frame: up to 2 weeks post-procedure
Surgery due to a procedure-related adverse event
Time frame: up to 2 weeks post-procedure
Post-interventional complications
Time frame: up to 3 years post-procedure
Other procedure-related complications
Contact information is provided by the study sponsor or research team.
Bettina Stritzke
CONTACT
Marc O. Schurr, Prof. Dr.
CONTACT
Ovesco Endoscopy AG
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07582003
Adenoma, Colonic Diseases
Los Angeles, California, United States
View Trial DetailsNCT07307547
Adenoma, Colonic Diseases
Hangzhou, Zhejiang, China
View Trial DetailsNCT02288962
Adenoma, Brain Diseases
Oslo, Norway
View Trial DetailsNCT07198945
Adenoma, Colon Cancer
Birmingham, Alabama, United States
View Trial Details